Malin Corporation has asked the High Court to approve a €110 million capital reduction to create distributable reserves for a well-flagged shareholder payout. Domiciled and headquartered in Dublin, the life sciences company is capitalising on the divestment of its stake in CG Oncology to return circa €45 million to its members. The background to the application was set out in an affidavit sworn by Fiona Dunlevy, executive director and company secretary of the PLC, grounding a successful application on Monday for the case to be fast-tracked into the commercial division of the High Court. On July 23, 2024, Malin announced…

Read on for just €1

For a limited time, get your first month for €1 and unlock full access to The Currency and The Wall Street Journal – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .